SLDB at a glance
Solid Biosciences Inc. (SLDB, SEC CIK 1707502) filed its latest 10-K annual report on March 19, 2026, a 10-Q quarterly report on August 6, 2026, an 8-K current report on August 6, 2026 and Form 4 insider filings as recently as October 6, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- As of June 30, 2026, 26 institutional investment managers tracked by SignalX reported holding Solid Biosciences Inc. (SLDB) shares worth $369.0 million in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 26 funds
- $369.0M · +0 vs prior quarter
- Latest 8-K
- Aug 6, 2026
- Item 8.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Revenue $0, unchanged YoY; no commercial product revenue generated
- Net loss $54.8M vs $39.5M YoY, up 38.8%; operating expenses $57.4M vs $41.7M
- SGT-212 R&D $2.4M, up 106.5%; SGT-601 lowest at $0.02M, down 99.0%
- Cash, equivalents and securities $377.7M at June 30, 2026, funding operations into mid-2028
- Near-term catalysts: FDA SGT-003 meeting planned late Q4 2026; initial SGT-212 data anticipated Q1 2027
Risk Factors
- Net losses $111.5 million for six months ended June 30, 2026, versus $78.8 million in 2025
- Funding runway into mid-2028, with additional capital required thereafter
- Uninsured bank deposits exceeding the FDIC limit of $250,000, creating liquidity-access risk
- Non-human-primate sourcing constraints could delay IND-enabling studies and Candidate progression
- Two treatment-related serious adverse events previously disclosed in INSPIRE DUCHENNE, though both resolved
AI summary of the SLDB 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 8.01: Other Events
- New prospectus supplement permits up to $200.0 million in additional common-stock sales through Jefferies
- Approximately $85.0 million already raised under the prior supplement, which is now superseded
Item 5.07: Submission of Matters to a Vote of Security Holders
- Shareholders elected Clare Kahn, Adam Stone, and Lynne Sullivan as Class II directors through the 2029 annual meeting
- PricewaterhouseCoopers LLP ratified as independent auditor for fiscal year 2026 with 86.4 million votes for
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Ilan Ganot shifted from Class III to Class I effective April 10, 2026, preserving equal Board-class membership
- Class III director count decreased to three; Class I increased to three
AI summaries of SLDB 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for SLDB
Don't miss the next SLDB filing
- Alerts as it files. A push when SLDB files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut SLDB, by share count.
- Ask anything. An AI agent that reads every SLDB filing and answers with sources.
SLDB alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| SMITH IAN F | M | Oct 2, 2026 | 3,440 | - |
| SMITH IAN F | M | Oct 2, 2026 | 3,440 | - |
| SMITH IAN F | M | Jul 2, 2026 | 3,440 | - |
| SMITH IAN F | M | Jul 2, 2026 | 3,440 | - |
| Freed Martin I | A | Jun 10, 2026 | 77,500 | - |
| Kahn Clare | A | Jun 10, 2026 | 77,500 | - |
| Ganot Ilan | A | Jun 10, 2026 | 77,500 | - |
| Stone Adam Leo | A | Jun 10, 2026 | 77,500 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Operating Income | - | -$129.7M | -$179.2M |
| Net Income | -$96.0M | -$124.7M | -$174.3M |
| Balance Sheet | |||
| Total Assets | $164.9M | $188.7M | $232.5M |
| Equity | $126.5M | $137.2M | $180.0M |
| ROE | -75.9% | -90.9% | -96.8% |
| Per Share | |||
| EPS | $-4.83 | $-3.06 | $-1.99 |
| Cash Flow | |||
| Operating CF | -$94.2M | -$100.0M | -$156.3M |
| CapEx | $1.5M | $654K | $1.2M |
Source: XBRL data in Solid Biosciences Inc. (SLDB)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate SLDB share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 26 | $369.0M |
| Q1 2026 | 26 | $177.4M |
| Q4 2025 | 23 | $101.5M |
| Q3 2025 | 24 | $128.4M |
| Q2 2025 | 23 | $100.2M |
| Q1 2025 | 20 | $43.1M |
| Q4 2024 | 14 | $18.0M |
| Q3 2024 | 12 | $22.5M |
- FMR LLC (Fidelity)+3.27M (+91%)
- State Street Corp+3.05M (+271%)
- BlackRock+1.98M (+40%)
- Vanguard Capital Management LLC+1.34M (+50%)
- Franklin Resources+1.25M (+57%)
- Ameriprise Financial−213.1K (-9%)
- Invesco Ltd−197.5K (-58%)
- Renaissance Technologies LLC−42.2K (-34%)
- Two Sigma Investments−31.5K (-34%)
- AQR Capital Management−14.5K (-10%)
- Prudential Financial+13.0K
- Millennium Management−363.7K
Source: 13F-HR filings on SEC EDGAR (aggregated from 168 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
SLDB filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Oct 6, 2026 | - | - | - |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 10-Q | Aug 6, 2026 | Jun 30, 2026 | Analysis | |
| SC 13G | Aug 6, 2026 | - | - | |
| SC 13G | Jul 30, 2026 | - | - | |
| 4 | Jul 7, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 8-K | Jun 10, 2026 | - | Analysis | |
| 10-Q | May 12, 2026 | Mar 31, 2026 | Analysis | |
| 4 | Apr 21, 2026 | - | - | - |
| 4 | Apr 21, 2026 | - | - | - |
| 4 | Apr 21, 2026 | - | - | - |
| 4 | Apr 21, 2026 | - | - | - |
| 4 | Apr 21, 2026 | - | - | - |
| 4 | Apr 21, 2026 | - | - | - |
| 8-K | Apr 10, 2026 | - | Analysis | - |
| 4 | Apr 2, 2026 | - | - | - |
Related Health Care companies
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- ADPT · Adaptive Biotechnologies CorpBiological Products, (No Diagnostic Substances)
- ADMA · ADMA BIOLOGICS, INC.Biological Products, (No Diagnostic Substances)
- ALEC · Alector, Inc.Biological Products, (No Diagnostic Substances)
- ALLO · Allogene Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AMGN · AmgenBiological Products, (No Diagnostic Substances)
- AVXL · ANAVEX LIFE SCIENCES CORP.Biological Products, (No Diagnostic Substances)
- APGE · Apogee Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
SLDB SEC filings: frequently asked questions
Which institutions hold SLDB stock?
As of June 30, 2026, the largest Solid Biosciences Inc. (SLDB) holders among the 13F filers tracked by SignalX were BlackRock ($69.3 million), FMR LLC (Fidelity) ($68.7 million), State Street Corp ($41.7 million), Vanguard Capital Management LLC ($40.1 million), Franklin Resources ($34.4 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What did SLDB report in its latest 8-K?
Solid Biosciences Inc. (SLDB) filed an 8-K on August 6, 2026 reporting Item 8.01 (Other Events). New prospectus supplement permits up to $200.0 million in additional common-stock sales through Jefferies.
What are the latest SLDB SEC filings?
Solid Biosciences Inc. (SLDB) filed its latest 10-K annual report on March 19, 2026, a 10-Q quarterly report on August 6, 2026, an 8-K current report on August 6, 2026 and a Form 4 insider filing on October 6, 2026.
What is SLDB's SEC CIK number?
Solid Biosciences Inc. (SLDB)'s SEC Central Index Key (CIK) is 1707502. EDGAR lists every SLDB filing under that number.
Ask anything about SLDB
The research agent reads SLDB's filings, financials, insider trades and 13F holders, then answers with sources.